Scientists have uncovered two related cytokines and associated genetic markers that may explain why some people develop progressive multiple sclerosis, or MS. The study, led by researchers at OHSU in Portland, Oregon, and Yale University, point the way toward developing the first-ever treatment to prevent progressive forms of the disease.
Scientists have uncovered two related cytokines and associated genetic markers that may explain why some people develop progressive multiple sclerosis, or MS. The study, led by researchers at OHSU in Portland, Oregon, and Yale University, point the way toward developing the first-ever treatment to prevent progressive forms of the disease.
The research was published today in the Proceedings of the National Academy of Sciences.
Researchers identified a cytokine, called macrophage migration inhibitory factor, or MIF, along with its homolog protein D-dopachrome tautomerase, or D-DT, that are associated with progressive MS. Cytokines are a type of protein that are important in signaling between cells in the body. These particular cytokines can worsen the disease by increasing inflammation within the central nervous system. Researchers also identified two genetic markers that enhance expression of MIF, and D-DT, that occurred more frequently in MS patients with progressive disease, particularly in men.
These findings suggest that a simple genetic test could be used to identify MS patients at risk of developing the more severe form of the disease. Even better, researchers are already developing a medication to stop the disease in its tracks.
Read more at Oregon Health & Science University
Image: Scientists have determined that the two cytokines, macrophage migration inhibitory factor (MIF) and its twin, D-DT are thought to influence the development of progressive MS. This illustration shows the predicted binding interaction between MIF (center) and three DC74 molecules. (Credit: OHSU)
